EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Update: Immunotherapeutic Strategies in HPV-Associated Head and Neck Squamous Cell Carcinoma

Fangdi Sun iD, A Dimitrios Colevas iD

Viruses · 2025

DOI: 10.3390/v17050712 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2025. Verfasst von Fangdi Sun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Papillomavirus Infections, Immunotherapy, Head and Neck Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The incidence of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has increased substantially over the past three decades, and since 2017, it has been recognized in the AJCC staging system as distinct from its HPV-negative counterpart. The underlying mechanisms of HPV-associated carcinogenesis, tumor microenvironment, and host immune response represent opportunities for therapeutic development. While anti-PD-1 immunotherapy is now part of standard treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in general, there are no established immunotherapeutic strategies specifically for HPV-related HNSCC. In this context, multiple emerging approaches are being actively studied—among these are therapeutic vaccines with or without anti-PD-(L)1 adjuvants, peptide–HLA-based immunotherapeutic platforms, and adoptive cell therapies including tumor-infiltrating lymphocytes (TILs), T-cell receptor (TCR) therapy, and chimeric antigen receptor (CAR) T-cell therapy. Beyond further maturation of these novel immunotherapeutic strategies, additional work is needed to delineate the optimal disease state of application (localized versus recurrent/metastatic), as well as in the development of small molecule inhibitors targeting HPV-specific mechanisms of viral oncogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Squamous Cell Carcinoma of Head and NeckPapillomavirus InfectionsImmunotherapyHead and Neck NeoplasmsPapillomaviridaeHumansTumor MicroenvironmentImmunotherapy, AdoptiveCancer Vaccines

Stichwörter der Autor:innen

adoptive T-cell therapyhead and neck cancerhuman papillomavirus (HPV)immune checkpoint inhibitorimmunotherapyoropharyngeal cancersquamous cell carcinoma

Substanzen

Cancer Vaccines

Autor:innen und Institutionen

  • Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.

ORCID-Profile: Fangdi Sun, A Dimitrios Colevas

Zitieren

APA

Sun, F., & Colevas, A. D. (2025). Update: Immunotherapeutic Strategies in HPV-Associated Head and Neck Squamous Cell Carcinoma. Viruses. https://doi.org/10.3390/v17050712

Vancouver

Sun F, Colevas AD. Update: Immunotherapeutic Strategies in HPV-Associated Head and Neck Squamous Cell Carcinoma. Viruses. 2025. doi:10.3390/v17050712

BibTeX
@article{Sun2025,
  author = {Sun, Fangdi and Colevas, A Dimitrios},
  title = {Update: Immunotherapeutic Strategies in HPV-Associated Head and Neck Squamous Cell Carcinoma},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17050712}
}
Kostenlos starten →